Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373347 · ClinicalTrials.gov registry record
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
A clinical trial of Liver Cancer, sponsored by Stanford University.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT00373347 is a study of Liver Cancer that is actively recruiting participants, run by Stanford University. The registered enrollment target is 600 participants, above the 440-participant average among 78 other Liver Cancer trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00373347, a study of Liver Cancer, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Conditions Studied
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2004-11 |
| Est. Completion | 2025-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373347
The ClinicalTrials.gov registry entry for NCT00373347 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 440-participant average among 78 other Liver Cancer trials with a reported enrollment target (36% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00373347 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00373347 about?
NCT00373347 is a clinical study titled "Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma". The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
What is the current status of trial NCT00373347?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2004-11. Estimated completion is 2025-12.
What conditions does trial NCT00373347 study?
This clinical trial studies the following conditions: Liver Cancer.
Who is sponsoring clinical trial NCT00373347?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373347 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Feasibility Study of CBCT for IGRT in Cancer Patients
RECRUITING · NA
-
Collection of Blood From Patients With Cancer
RECRUITING
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
RECRUITING · NA
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.